Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples